Palmitoylethanolamide slows the activity of so-called mast cells, certain inflammation cells and also works as a pain relief and anti inflammatory due to specific activity on a certain important receptor in the cell nucleus, the so called PARR receptor. This is why it’s easy to understand why palmitoylethanolamide (PEA) could be used to treat so many symptoms. All these ailments have chronic pain or inflammation in common. Here you will find the potential circle of indications for palmitoylethanolamide, based on pharmaceutical studies, preclinical animal studies and clinical studies.

This circle of indications was designed for inter collegial consult and discussion with doctors that consult our center related to the treatment of their patients. The circle is not meant to be a claim to the effectiveness or PEA in all of these indications!

Circle of indications for palmitoylethanolamide: working mechanisms.

Palmitoylethanolamide is available as a supplement. Palmitoylethanolamide is a safe and effective means to treat chronic pain and inflammation.

The indications below make sense considering palmitoylethanolamide slows the activity of the so-called mast cells [2] [3], as well as the activity of stressed-out nerve cells and glial cells, which all go in overdrive during chronic pain [4]. Palmitoylethanolamide (PEA) is an entirely new method of treatment, using a molecule that restores balance and protects the cells of the body [5] [6]. The pain relieving and anti-inflammatory properties of PEA can easily be understood by the biology of the substance [7][8][9].

The 14 mechanisms by which PEA works form the basis of understanding that PEA can be used for a plethora of ailments, as described in the circle of indications below.

The slowing down of derailed mast cells and other inflammatory cells is cause, amongst other reasons, by resetting the interruptions in the physiology of the cell through the so-called nucleus receptor. [10][11][12][13][14]. There are many natural mechanisms, besides the nucleus receptor, through which this special molecule restores balance in the body. These have been depicted on the side. [15]

 

Chronic pain syndromes

General chronic pain syndromes [16] [17][18][19][20][21][20][23][24][25][26][27][28][29][30][31][32]
Pain and spasms due to MS [33][34]
Hernia and back pain [35][36][37][38][39]
Diabetic neuropathic pain[40][41][42] [41][44][45]
Herpes and shingles pain (gordelroospijn) [46][47]
Neuropathic pain from different types of neuropathy, CIAP, CIDP, etc [24][49][50][51][52]
Carpal tunnel syndrome [53] [54]
Chemotherapy induced neuropathic pain [55]
Complex regional pain syndrome, Sudeck [56][57]
Pain and painful spasms due to multiple scleroses [58] [59] [60] [61] [62][63][64][65][66][67][68]
Central neuropathic pain due to stroke [69][70][71][72][73]
Central neuropathic pin due to syringomyelia and paraplegia [58][75]
Migraine [76][77][78][79]
Occipital neuralgia [80][81]
Fibromyalgia [82][83]
Rheumatism; Rheumatoid arthritis en Bechterew pains [84][85][86]
Arthritis psoriatic [87]
Costen syndrome, arthritis of the jaw, temporomandibular pain syndrome [88][89]
Chronic pruritis, unexplained itch [90]
Pin and itch after chemotherapy [91]
Chronic Idiopathic axonal neuropathy pain [92]
Visceral pain syndrome [93][27][26][96]

 

Nerve protection and recovery

Protection and recovery of nervous system [97][98][99][100][101][102][103]

 

Urogenital pain syndrome (bladder, prostate, vagina)

In case of unexplained painful inflammation, when the urologist has ruled out cancer en there is no case of chronic infection due to bacteria, the anti-inflammatory and pain relieving PEA is a good move. On top of that, PEA protects the kidneys  [104]

 

Chronic painful prostate complaints

Chronic prostate pain (prostatodynia) [105][105][107]

When the Gynecologist or urologist ruled out infection and there is unexplained inflammation in the inside of the bladder, with pain, difficulty urinating, urinating small quantities etc, taking PeaCure can be useful.

 

Interstitial cystitis and bladder pain

Interstitial cystitis[108][109]
Chronic bladder pain[110][111][112][113][114]

 

Pain, burning and inflammation of the vagina, vulva and other gynecological indications.

Lichen planus with itching and pain [115]
Vulvar vestibulitis [116][117][118][119]
Vulvodynia, vestibulodynia  [120][121][122][123]
Perineodynia (unexplained pain in the pelvis) [124]
Endometriosis  [125][126][127][128]
Menstrual pains [129]

 

Gastrointestinal indications

Intestinal (and colon) inflammation and pain syndromes [21][131][132][133][134][135][136]
Ulcerative Colitis [137][138][139][136][133]
Crohn’s disease  [142][143][144]
Irritable bowel syndrome [145][146]
Proctitis [147][148][147]
Chronic unexplained stomach aches [150][146]

Skin disorders

Chronic unexplained skin inflammation [28] [153] [154] [155] [156]
Chronic unexplained itching [157][90]
Atopic and contact dermatitis [159] [160] [161][162][163][164][165][166]
Psoriasis [167] [168] [169]
Paresthetica notalgia 

 

Other conditions

Asthma and COPD [170] [171][172][173]
Arthritis, inflammation of the joints [174]
Hay fever and allergic rhinitis [175]
Angina pectoris and Kounis syndrome [176] [177][178][179][180]
Progressive arteriosclerosis hypertension [181][182]
Ocular hypertension [183][184][185][186][187]
Chronic eye infections [188]
Depression and anxiety [189][190][191][192]
Epilepsy [193][194][195]
Parkinson’s disease [196]
Stroke [197][198] en spasms [34]
Amyotrophic lateral sclerosis [200][201]
Alzheimer [202] [18] [204][205][206][207][208][209]
Neuroinflammation disorders [210][211][201]
Paraplegia [58]
Flu and common cold, infections [214][215]
Cancerer (as adjuvant) [216][217][218][219][220][221][222][223][224]and pains due to cancer
General chronic inflammation [225][226][227][228][229][230][231][232]
Strengthening the immune system[233]
Blood pressure regulation [234]
Addiction related problems [235]

Below is the circle of indications for palmitoylethanolamide.

Circle-of-Indications-for-PeaCure
Circle-of-Indications-for-PeaCure

All potential indications of PEA are pictured in the hexagram below, divided in six groups of conditions.

 

Reference

[1] Weller CL, Collington SJ, Williams T, Lamb JR. | Mast cells in health and disease. | Clin Sci (Lond). |2011 Jun;120(11):473-84.

[2] De Filippis D, Negro L, Vaia M, Cinelli MP, Iuvone T. | New Insights in Mast Cell Modulation by Palmitoylethanolamide. | CNS Neurol Disord Drug Targets. | 2013 Feb 4. [Epub ahead of print]

[3] Luongo L, Guida F, Boccella S, Bellini G, Gatta L, Rossi F, de Novellis V, Maione S. |Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. | CNS Neurol Disord Drug Targets. | 2013 Feb 4. [Epub ahead of print]

[4] Skaper SD, di Marzo V. | Palmitoylethanolamide: Biochemistry, Pharmacology and Therapeutic Use of a Pleiotropic Anti-Inflammatory Lipid Mediator. | CNS Neurol Disord Drug Targets. | 2013 Feb 4. [Epub ahead of print]

[5] Bettoni I, Comelli F, Colombo A, Bonfanti P, Costa B. | Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide. | CNS Neurol Disord Drug Targets. | 2013 Feb 4. [Epub ahead of print]

[6] Petrosino S1, Schiano Moriello A, Cerrato S, Fusco M, Puigdemont A, De Petrocellis L, Di Marzo V. | The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. | Br J Pharmacol. | 2015 Jan 19. doi: 10.1111/bph.13084. [Epub ahead of print]

[7] Alhouayek M1, Muccioli GG2. | Harnessing the anti-inflammatory potential of palmitoylethanolamide. |Drug Discov Today. | 2014 Oct;19(10):1632-9. doi: 10.1016/j.drudis.2014.06.007. Epub 2014 Jun 17.

[8] Yamashita M. | PPARalpha/gamma-Independent Effects of PPARalpha/gamma Ligands on Cysteinyl Leukotriene Production in Mast Cells. | PPAR Res. | 2008;2008:293538. Epub 2008 Nov 9.

[9] Cabrero A, Laguna JC, Vázquez M. | Peroxisome proliferator-activated receptors and the control of inflammation. | Curr Drug Targets Inflamm Allergy. | 2002 Sep;1(3):243-8.

[10] Khasabova IA, Xiong Y, Coicou LG, Piomelli D, Seybold V. | Peroxisome Proliferator-Activated Receptor α Mediates Acute Effects of Palmitoylethanolamide on Sensory Neurons. | J Neurosci. | 2012 Sep 12;32(37):12735-43.

[11] Tachibana M, Wada K, Katayama K, Kamisaki Y, Maeyama K, Kadowaki T, Blumberg RS, Nakajima A. |Activation of peroxisome proliferator-activated receptor gamma suppresses mast cell maturation involved in allergic diseases. | Allergy. | 2008 Sep;63(9):1136-47. Epub 2008 Jun 10.

[12] Grygiel-Górniak B1. | Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications–a review. | Nutr J. | 2014 Feb 14;13:17. doi: 10.1186/1475-2891-13-17.

[13] Mattace Raso G1, Russo R1, Calignano A2, Meli R1. | Palmitoylethanolamide in CNS health and disease. | Pharmacol Res. | 2014 Aug;86:32-41. doi: 10.1016/j.phrs.2014.05.006. Epub 2014 May 17.

[14] DiPaolo A et al. Palmitoylethanolamide as a treatment for vaious chronic painstates. Presented at the 34 AISD congress in Riccione, 2011 |

[15] D’Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E, Mattace Raso G, Cuzzocrea S, Loverme J, Piomelli D, Meli R, Calignano A. | Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. | Eur J Pharmacol.| 2009 Jun 24;613(1-3):54-9. Epub 2009 Apr 20.

[16] Scuderi C, Esposito G, Blasio A, Valenza M, Arietti P, Steardo L Jr, Carnuccio R, De Filippis D, Petrosino S, Iuvone T, Di Marzo V, Steardo L. | Palmitoylethanolamide counteracts reactive astrogliosis induced by beta-amyloid peptide. | J Cell Mol Med. | 2011 Jan 21. doi: 10.1111/j.1582-4934.2011.01267.x. [Epub ahead of print]

[17] Cerrato S, Brazis P, della Valle MF, Miolo A, Puigdemont A. | Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells. | Vet Immunol Immunopathol. | 2010 Jan 15;133(1):9-15. Epub 2009 Jun 27.

[18] Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. | The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. | Pain. | 2008 Oct 31;139(3):541-50. Epub 2008 Jul 3.

[19] De Filippis D, D’Amico A, Iuvone T. | Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. | J Neuroendocrinol. | 2008 May;20 Suppl 1:20-5.

[20] Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. | The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. | Pain. | 2008 Oct 31;139(3):541-50. Epub 2008 Jul 3.

[21] Jhaveri MD, Richardson D, Robinson I, Garle MJ, Patel A, Sun Y, Sagar DR, Bennett AJ, Alexander SP, Kendall DA, Barrett DA, Chapman V. | Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. | Neuropharmacology. | 2008 Jul;55(1):85-93. Epub 2008 Apr 29.

[22] Wallace VC, Segerdahl AR, Lambert DM, Vandevoorde S, Blackbeard J, Pheby T, Hasnie F, Rice AS. |The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy. | Br J Pharmacol. | 2007 Aug;151(7):1117-28. Epub 2007 Jun 11.

[23] LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G, Meli R, Hohmann A, Calignano A, Piomelli D. | Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. | J Pharmacol Exp Ther. | 2006 Dec;319(3):1051-61. Epub 2006 Sep 22.

[24] Farquhar-Smith WP, Rice AS. | Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. | Anesthesiology. | 2001 Mar;94(3):507-13; discussion 6A.

[25] Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. | The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. | Pain. | 1998 May;76(1-2):189-99.

[26] De Filippis D, Luongo L, Cipriano M, Palazzo E, Cinelli MP, de Novellis V, Maione S, Iuvone T. |Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. | Mol Pain. | 2011 Jan 10;7:3.

[27] Matzke AJ, Weiger TM, Matzke MA. | Detection of a large cation-selective channel in nuclear envelopes of avian erythrocytes. | FEBS Lett. | 1990 Oct 1;271(1-2):161-4.

[28] Ford GK, Kieran S, Dolan K, Harhen B, Finn DP. | A role for the ventral hippocampal endocannabinoid system in fear-conditioned analgesia and fear responding in the presence of nociceptive tone in rats. | Pain.| 2011 Aug 22. [Epub ahead of print]

[29] Ambrosino P, Soldovieri MV, Russo C, Taglialatela M. | Activation and desensitization of TRPV1 channels in sensory neurons by the PPAR? agonist palmitoylethanolamide. | Br J Pharmacol. | 2013 Mar;168(6):1430-44. doi: 10.1111/bph.12029.

[30] González-Hernández A1, Martínez-Lorenzana G, Rodríguez-Jiménez J, Rojas-Piloni G, Condés-Lara M. |Intracisternal injection of palmitoylethanolamide inhibits the peripheral nociceptive evoked responses of dorsal horn wide dynamic range neurons. | J Neural Transm. | 2015 Mar;122(3):369-74. doi: 10.1007/s00702-014-1255-6. Epub 2014 Jun 12.

[31] Mancardi GL et al. Palmitoylethanolamide in neuropathic pain in MS patients. Presented at the 15yh Italian neurological meeting in Padua, 2009 |

[32] Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di Marzo V. | Endocannabinoids control spasticity in a multiple sclerosis model. | FASEB J. | 2001 Feb;15(2):300-2. Epub 2000 Dec 8.

[33] G. Guida, A. de Fabiani, F. Lanaia, A. Alexandre, G.M. Vassallo, L. Cantieri, M. de Martino, M. Rogai, S. Petrosino | La palmitoiletanolamida (Normast) en el dolor neuropatico cronico por lumbociatalgia de tipo compresivo: estudio clinico multicentrico. | Dolor | 2010, 25:35-42

[34] Desio,P et al. | Efficacy of palmitoylethanolamide and oxycodon in patients with low back pain. Anesthesia and medicina critica (AMC) 2011, 2: 62-71.

[35] Palomba R et al. | Efficacy of palmitoylethanolamide as part of multimodal analgesic therapy in patients with low back pain. Presented at 33rd AISD congress, 2010, Florence

[36] Dominguez CM et al. Palmitoylethanolamide on standard care in lumbosciatic pain, a pragmatic trial. Preseted at 8th congres of Pain algologists, Madrid, 2010. |

[37] Canteri L et al. Reduction of analgesics in patients suffering from lumbosciatic pain, treated with palmitoylethanolamide. Dolor 2010 | 25:227-234

[40] Biasiotta A, La Cesa S, Leone C, Di Stefano G, Truini A, Cruccu G. | Efficacy of palmitoylethanolamide in patients with painful neuropathy. A clincial and neurophysiological open study. Preliminary results. | , Volume 4, Issue 1, May 2010, Page 77.

[41] Matias I, Wang JW, Moriello AS, Nieves A, Woodward DF, Di Marzo V. | Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. | Prostaglandins Leukot Essent Fatty Acids. | 2006 Dec;75(6):413-8. Epub 2006 Oct 2.

[42] Schifiliti C, et al. Efficacy of palmitoylethanolamide in pain and neuropathic symptoms in diabetic patients Presentation at IV congress of European Schock society, Taormina, 2011 

[43] Matias I, Wang JW, Moriello AS, Nieves A, Woodward DF, Di Marzo V. | Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. | Prostaglandins Leukot Essent Fatty Acids. | 2006 Dec;75(6):413-8. Epub 2006 Oct 2.

[44] Adiletta S et al. Pregabalin and Palmitoylethanolamide in diabetic neuropathic pain: an randomized clinical trial. Presented at the 34th AISD meeting, 2011, Riccione. |

[45] Donvito G, Bettoni I, Comelli F, Colombo A, Costa B1. | Palmitoylethanolamide relieves pain and preserves pancreatic islet cells in a murine model of diabetes. | CNS Neurol Disord Drug Targets. |2015;14(4):452-62.

[46] Phan NQ, Siepmann D, Gralow I, Ständer S. | Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. | J Dtsch Dermatol Ges. | 2010 Feb;8(2):88-91. Epub 2009 Sep 10.

[47] Deslo. P. Combination of pregabalin and palmitoylethanolamide (PEA) for neuropathic pain treatment.| Pathos, 2010, 17,4:9-14

[48] Wallace VC, Segerdahl AR, Lambert DM, Vandevoorde S, Blackbeard J, Pheby T, Hasnie F, Rice AS. |The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy. | Br J Pharmacol. | 2007 Aug;151(7):1117-28. Epub 2007 Jun 11.

[49] Desio P, Pregabalin and Palmitoylethanolamide in the treatment of neuropathic pain. Pathos 2010l17:9-14 |

[50] Starowicz K, Przewlocka B. | Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system. | Philos Trans R Soc Lond B Biol Sci. | 2012 Dec 5;367(1607):3286-99. doi: 10.1098/rstb.2011.0392.

[51] Cocito D1, Peci E1, Ciaramitaro P1, Merola A1, Lopiano L1. | Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. | Pain Res Treat. | 2014;2014:854560. doi: 10.1155/2014/854560. Epub 2014 May 20.

[52] Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, Giusti P. | Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. | Inflammopharmacology. | 2013 Nov 1. [Epub ahead of print]

[53] Assini A, Laricchia D, Pizzo R, Pandolfini L, Belletti M, Colucci M, Ratto S. | P1577: The carpal tunnel syndrome in diabetes: clinical and electrophysiological improvement after treatment with palmitoylethanolamide | Eur J Neurol | 2010: 17(S3):295.

[54] Conigliaro R, Drago V, Foster PS, Schievano C, Di Marzo V. | Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist. | Minerva Med. | 2011 Apr;102(2):141-7.

[55] Truina A et al. Palmitoylethanolamide improves pain and nerve function in patients suffering from chemotherapy induced neuropathy. CNS and neurological drug target, 2011, submitted.

[58] Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Galuppo M, Cuzzocrea S. | Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. |Brain Behav Immun. | 2011 Feb 25. [Epub ahead of print]

[59] Jean-Gilles L, Feng S, Tench CR, Chapman V, Kendall DA, Barrett DA, Constantinescu CS. | Plasma endocannabinoid levels in multiple sclerosis. | J Neurol Sci. | 2009 Dec 15;287(1-2):212-5. Epub 2009 Aug 20.

[60] Zajicek JP, Apostu VI. | Role of cannabinoids in multiple sclerosis. | CNS Drugs. | 2011 Mar 1;25(3):187-201. doi: 10.2165/11539000-000000000-00000.

[61] Loría F, Petrosino S, Mestre L, Spagnolo A, Correa F, Hernangómez M, Guaza C, Di Marzo V, Docagne F. | Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. | Eur J Neurosci. | 2008 Aug;28(4):633-41. Epub 2008 Jul 24.

[62] Cabranes A, Venderova K, de Lago E, Fezza F, Sánchez A, Mestre L, Valenti M, García-Merino A, Ramos JA, Di Marzo V, Fernández-Ruiz J. | Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. |Neurobiol Dis. | 2005 Nov;20(2):207-17.

[63] Maccarrone M, Bernardi G, Agrò AF, Centonze D. | Cannabinoid receptor signaling in neurodegenerative diseases: a potential role for membrane fluidity disturbance. | Br J Pharmacol. | 2011 Feb 16. doi: 10.1111/j.1476-5381.2011.01277.x. [Epub ahead of print]

[64] Bisogno T, Di Marzo V. | Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. | CNS Neurol Disord Drug Targets. | 2010 Nov;9(5):564-73.

[65] Correa F, Hernangómez-Herrero M, Mestre L, Loría F, Docagne F, Guaza C. | The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. | Brain Behav Immun. | 2011 May;25(4):736-49. Epub 2011 Feb 16.

[66] Rossi S, Bernardi G, Centonze D. | The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. | Exp Neurol. | 2010 Jul;224(1):92-102. Epub 2010 Mar 29.

[67] Loría F, Petrosino S, Hernangómez M, Mestre L, Spagnolo A, Correa F, Di Marzo V, Docagne F, Guaza C. | An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. | Neurobiol Dis. | 2010 Jan;37(1):166-76. Epub 2009 Oct 6.

[68] Correa FG, Mestre L, Docagne F, Borrell J, Guaza C. | The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis. | Vitam Horm. | 2009;81:207-30.

[69] Naccarato M, Pizzuti D, Petrosino S, Simonetto M, Ferigo L, Grandi FC, Pizzolato G, Di Marzo V. |Possible Anandamide and Palmitoylethanolamide involvement in human stroke. | Lipids Health Dis. | 2010 May 14;9:47.

[70] Hansen HS. | Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. | Exp Neurol. | 2010 Jul;224(1):48-55. Epub 2010 Mar 29.

[71] Koch M, Kreutz S, Böttger C, Benz A, Maronde E, Ghadban C, Korf HW, Dehghani F. |Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferator-activated receptor-alpha. | Neurotox Res. | 2011 Feb;19(2):330-40. Epub 2010 Mar 11.

[72] Schomacher M, Müller HD, Sommer C, Schwab S, Schäbitz WR. | Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia. | Brain Res. | 2008 Nov 13;1240:213-20. Epub 2008 Sep 18.

[73] Gray E, Ginty M, Kemp K, Scolding N, Wilkins A. | Peroxisome proliferator-activated receptor-α agonists protect cortical neurons from inflammatory mediators and improve peroxisomal function. | Eur J Neurosci. | 2011 Apr;33(8):1421-32. doi: 10.1111/j.1460-9568.2011.07637.x. Epub 2011 Mar 7.

[74] Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Galuppo M, Cuzzocrea S. | Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. |Brain Behav Immun. | 2011 Feb 25. [Epub ahead of print]

[75] Genovese T, Esposito E, Mazzon E, Di Paola R, Meli R, Bramanti P, Piomelli D, Calignano A, Cuzzocrea S. | Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. | J Pharmacol Exp Ther. | 2008 Jul;326(1):12-23. Epub 2008 Mar 26.

[76] Sarchielli P, Pini LA, Coppola F, Rossi C, Baldi A, Mancini ML, Calabresi P. | Endocannabinoids in chronic migraine: CSF findings suggest a system failure. | Neuropsychopharmacology. | 2007 Jun;32(6):1384-90. Epub 2006 Nov 22.

[77] Levy D. | Migraine pain, meningeal inflammation, and mast cells. | Curr Pain Headache Rep. | 2009 Jun;13(3):237-40.

[78] Levy D, Burstein R, Strassman AM. | Mast cell involvement in the pathophysiology of migraine headache: A hypothesis. | Headache. | 2006 Jun;46 Suppl 1:S13-8.

[79] Zhang XC, Strassman AM, Burstein R, Levy D. | Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. | J Pharmacol Exp Ther. | 2007 Aug;322(2):806-12. Epub 2007 May 4.

[80] Calabrò RS, Bramanti P. | Occipital Neuralgia Responding to Palmitoylethanolamide. | Headache. |2013 May 23. doi: 10.1111/head.12136. [Epub ahead of print]

[81] Cairns BE1, Laursen JC2, Dong XD3, Gazerani P4. | Intraganglionic injection of a nitric oxide donator induces afferent mechanical sensitization that is attenuated by palmitoylethanolamide. | Cephalalgia. | 2014 Feb 11;34(9):686-694. [Epub ahead of print]

[82] Blanco I, Béritze N, Argüelles M, Cárcaba V, Fernández F, Janciauskiene S, Oikonomopoulou K, de Serres FJ, Fernández-Bustillo E, Hollenberg MD. | Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients. | Clin Rheumatol. | 2010 Dec;29(12):1403-12. Epub 2010 Apr 30.

[83] Ghafouri N, Ghafouri B, Larsson B, Stensson N, Fowler CJ, Gerdle B. | Palmitoylethanolamide and stearoylethanolamide levels in the interstitium of the trapezius muscle of women with chronic widespread pain and chronic neck-shoulder pain correlate with pain intensity and sensitivity. | Pain. | 2013 May 14. pii: S0304-3959(13)00225-X. doi: 10.1016/j.pain.2013.05.002. [Epub ahead of print]

[84] Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. | Mast cells: a cellular link between autoantibodies and inflammatory arthritis. | Science. | 2002 Sep 6;297(5587):1689-92.

[85] Nigrovic PA, Lee DM. | Mast cells in autoantibody responses and arthritis. | Novartis Found Symp. |2005;271:200-9; discussion 210-4.

[86] Christy AL, Brown MA. | The multitasking mast cell: positive and negative roles in the progression of autoimmunity. | J Immunol. | 2007 Sep 1;179(5):2673-9.

[87] Cañete JD, Celis R, Noordenbos T, Moll C, Gómez-Puerta JA, Pizcueta P, Palacin A, Tak PP, Sanmartí R, Baeten D. | Distinct synovial immunopathology in Behçet disease and psoriatic arthritis. |Arthritis Res Ther. | 2009;11(1):R17. Epub 2009 Feb 6.

[88] Bortolotti F,Russo M, Bartolucci ML, Alessandri Bonetti G, Gatto MR, Marini I. | Palmitoylethanolamide vs NSAID in the treatment of TMJD Pain | Journal of Dental Research | 2010: 89(Special Issue B)

[89] Hugger A, Schindler HJ, Türp JC, Hugger S. | [Pharmacological therapy of temporomandibular joint pain]. | Z Evid Fortbild Qual Gesundhwes. | 2013;107(4-5):302-8. doi: 10.1016/j.zefq.2012.12.003. Epub 2013 Jan 11.

[90] Ständer S, Raap U, Weisshaar E, Schmelz M, Mettang T, Handwerker H, Luger TA. | Pathogenesis of pruritus. | J Dtsch Dermatol Ges. | 2011 Jun;9(6):456-463. doi: 10.1111/j.1610-0387.2011.07585.x. Epub 2011 Jan 5.

[91] Latif S, Fraga G, Gadzia J. | Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding. | J Drugs Dermatol. | 2010 Mar;9(3):268-70.

[93] Jaggar SI, Sellaturay S, Rice AS. | The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat urinary bladder. | Neurosci Lett. | 1998 Sep 4;253(2):123-6.

[94] Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. | The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. | Pain. | 1998 May;76(1-2):189-99.

[95] Farquhar-Smith WP, Rice AS. | Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. | Anesthesiology. | 2001 Mar;94(3):507-13; discussion 6A.

[96] Capasso R, Izzo AA, Fezza F, Pinto A, Capasso F, Mascolo N, Di Marzo V. | Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. | Br J Pharmacol. | 2001 Nov;134(5):945-50.

[97] Kapoor S. | Emerging neuroprotective effects of N-palmitoylethanolamide besides its significant antinociceptive effects. | Pain Med. | 2013 May;14(5):773-4. doi: 10.1111/pme.12118. Epub 2013 Apr 12.

[98] Di Cesare Mannelli L, D’Agostino G, Pacini A, Russo R, Zanardelli M, Ghelardini C, Calignano A. |Palmitoylethanolamide Is a Disease-Modifying Agent in Peripheral Neuropathy: Pain Relief and Neuroprotection Share a PPAR-Alpha-Mediated Mechanism. | Mediators Inflamm. | 2013;2013:328797. doi: 10.1155/2013/328797. Epub 2013 Feb 25.

[99] Esposito E, Cuzzocrea S. | Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries. | CNS Neurol Disord Drug Targets. | 2013 Feb 4. [Epub ahead of print]

[100] Paterniti I, Impellizzeri D, Crupi R, Morabito R, Campolo M, Esposito E, Cuzzocrea S. | Molecular evidence for the involvement of PPAR-? and PPAR-? in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma. | J Neuroinflammation. | 2013 Feb 1;10:20. doi: 10.1186/1742-2094-10-20.

[101] Skaper SD, Buriani A, Dal Toso R, Petrelli L, Romanello S, Facci L, Leon A. | The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. | Proc Natl Acad Sci U S A. | 1996 Apr 30;93(9):3984-9.

[102] Lin TY1,2, Lu CW3,4, Wu CC5, Huang SK6, Wang SJ7,8. | Palmitoylethanolamide inhibits glutamate release in rat cerebrocortical nerve terminals. | Int J Mol Sci. | 2015 Mar 11;16(3):5555-71. doi: 10.3390/ijms16035555.

[103] Fidaleo M, Fanelli F, Ceru MP, Moreno S1. | Neuroprotective properties of peroxisome proliferator-activated receptor alpha (PPAR?) and its lipid ligands. | Curr Med Chem. | 2014;21(24):2803-21.

[104] Impellizzeri D1, Esposito E1, Attley J2, Cuzzocrea S3. | Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD). | Pharmacol Res. | 2014 Mar;81:91-102. doi: 10.1016/j.phrs.2014.02.007. Epub 2014 Mar 3.

[105] Papadoukakis S, Kyroudi-Voulgari A, Truss MC, Perea D, Mitropoulos D. | Quantitative study of mast cells in experimentally induced benign prostatic hyperplasia. | Urol Int. | 2010;84(1):100-4. Epub 2010 Feb 17.

[106] Papadoukakis S, Kyroudi-Voulgari A, Truss MC, Perea D, Mitropoulos D. | Quantitative study of mast cells in experimentally induced benign prostatic hyperplasia. | Urol Int. | 2010;84(1):100-4. Epub 2010 Feb 17.

[107] Mehik A, Leskinen MJ, Hellström P. | Mechanisms of pain in chronic pelvic pain syndrome: influence of prostatic inflammation. | World J Urol. | 2003 Jun;21(2):90-4. Epub 2003 Apr 17.

[108] Butrick CW, Howard FM, Sand PK. | Diagnosis and treatment of interstitial cystitis/painful bladder syndrome: a review. | J Womens Health (Larchmt). | 2010 Jun;19(6):1185-93.

[109] Richter B, Roslind A, Hesse U, Nordling J, Johansen JS, Horn T, Hansen AB. | YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis. | Histopathology.| 2010 Sep;57(3):371-83. doi: 10.1111/j.1365-2559.2010.03640.x.

[110] Geurts N, Van Dyck J, Wyndaele JJ. | Bladder pain syndrome: do the different morphological and cystoscopic features correlate? | Scand J Urol Nephrol. | 2011 Feb;45(1):20-3. Epub 2010 Sep 17.

[111] Richter B, Hesse U, Hansen AB, Horn T, Mortensen SO, Nordling J. | Bladder pain syndrome/interstitial cystitis in a Danish population: a study using the 2008 criteria of the European Society for the Study of Interstitial Cystitis. | BJU Int. | 2010 Mar;105(5):660-7. Epub 2009 Sep 14.

[112] Larsen MS, Mortensen S, Nordling J, Horn T. | Quantifying mast cells in bladder pain syndrome by immunohistochemical analysis. | BJU Int. | 2008 Jul;102(2):204-7; discussion 207. Epub 2008 Jul 1.

[113] Rudick CN, Bryce PJ, Guichelaar LA, Berry RE, Klumpp DJ. | Mast cell-derived histamine mediates cystitis pain. | PLoS One. | 2008 May 7;3(5):e2096.

[114] Pessina F1, Capasso R2, Borrelli F2, Aveta T3, Buono L4, Valacchi G5, Fiorenzani P1, Di Marzo V3, Orlando P4, Izzo AA6. | Protective effect of palmitoylethanolamide in a rat model of cystitis. | J Urol. | 2015 Apr;193(4):1401-8. doi: 10.1016/j.juro.2014.11.083. Epub 2014 Nov 18.

[115] van de Nieuwenhof HP, Hebeda KM, Bulten J, Otte-Holler I, Massuger LF, de Hullu JA, van Kempen LC. | Specific intraepithelial localization of mast cells in differentiated vulvar intraepithelial neoplasia and its possible contribution to vulvar squamous cell carcinoma development. | Histopathology. | 2010 Sep;57(3):351-62. doi: 10.1111/j.1365-2559.2010.03635.x. Epub 2010 Aug 19.

[116] Bornstein J, Goldschmid N, Sabo E. | Hyperinnervation and mast cell activation may be used as histopathologic diagnostic criteria for vulvar vestibulitis. | Gynecol Obstet Invest. | 2004;58(3):171-8. Epub 2004 Jul 9.

[117] Halperin R, Zehavi S, Vaknin Z, Ben-Ami I, Pansky M, Schneider D. | The major histopathologic characteristics in the vulvar vestibulitis syndrome. | Gynecol Obstet Invest. | 2005;59(2):75-9. Epub 2004 Nov 11.

[118] Chadha S, Gianotten WL, Drogendijk AC, Weijmar Schultz WC, Blindeman LA, van der Meijden WI. |Histopathologic features of vulvar vestibulitis. | Int J Gynecol Pathol. | 1998 Jan;17(1):7-11.

[119] Murina F. et al. Palmitoylethanolamide and polidatina in the treatment of vestibulodynia, and the reduction of the C fibre activation. Presented at the world congress of pathology of the vulva, Parigi, september 2011 |

[120] Harlow BL, He W, Nguyen RH. | Allergic reactions and risk of vulvodynia. | Ann Epidemiol. | 2009 Nov;19(11):771-7.

[121] Goetsch MF, Morgan TK, Korcheva VB, Li H, Peters D, Leclair CM. | Histologic and receptor analysis of primary and secondary vestibulodynia and controls: a prospective study. | Am J Obstet Gynecol. | 2010 Jun;202(6):614.e1-8. Epub 2010 Apr 28.

[122] Murina F, Graziottin A, Felice R, Radici G, Tognocchi C. | Vestibulodynia: synergy between palmitoylethanolamide + transpolydatin and transcutaneous electrical nerve stimulation. | J Low Genit Tract Dis. | 2013 Apr;17(2):111-6. doi: 10.1097/LGT.0b013e3182652316.

[124] Calabrò RS, Gervasi G, Marino S, Mondo PN, Bramanti P. | Misdiagnosed chronic pelvic pain: pudendal neuralgia responding to a novel use of palmitoylethanolamide. | Pain Med. | 2010 May;11(5):781-4. Epub 2010 Mar 22.

[125] Indraccolo U, Barbieri F. | Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: preliminary observations. | Eur J Obstet Gynecol Reprod Biol. | 2010 May;150(1):76-9. Epub 2010 Feb 21.

[126] Lo Monte G, Soave I, Marci R. | [Administration of MICRONIZED PALMITOYLETHANOLAMIDE (PEA)-transpolydatin in the treatment of chronic pelvic pain in women affected by endometriosis: preliminary results.] | Minerva Ginecol. | 2013 Mar 13. [Epub ahead of print]

[127] Giugliano E, Cagnazzo E, Soave I, Lo Monte G, Wenger JM, Marci R. | The adjuvant use of N-palmitoylethanolamine and transpolydatin in the treatment of endometriotic pain. | Eur J Obstet Gynecol Reprod Biol. | 2013 Jun;168(2):209-13. doi: 10.1016/j.ejogrb.2013.01.009. Epub 2013 Feb 14.

[128] Iuvone T1, Affaitati G, De Filippis D, Lopopolo M, Grassia G, Lapenna D, Negro L, Costantini R, Vaia M, Cipollone F, Ialenti A, Giamberardino MA. | ULTRAMICRONIZED PALMITOYLETHANOLAMIDE REDUCES VISCERO-VISCERAL HYPERALGESIA IN A RAT MODEL OF ENDOMETRIOSIS PLUS URETERAL CALCULOSIS: ROLE OF MAST CELLS. | Pain. | 2015 May 6. [Epub ahead of print]

[129] Fulghesu A et al. Pain during menstruation in young adults treated with palmitoylethanolamide and polidatina. Presented at the 16th world congress for child and adolescent gynaecology, Montpellier, 2010 |

[130] De Filippis D, D’Amico A, Iuvone T. | Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. | J Neuroendocrinol. | 2008 May;20 Suppl 1:20-5.

[131] Theoharides TC, Alysandratos KD, Angelidou A, Delivanis DA, Sismanopoulos N, Zhang B, Asadi S, Vasiadi M, Weng Z, Miniati A, Kalogeromitros D. | Mast cells and inflammation. | Biochim Biophys Acta. |2010 Dec 23. [Epub ahead of print]

[132] Schicho R, Storr M. | Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases. | Can J Gastroenterol. | 2011 Jul;25(7):377-83.

[133] Esposito G1, Capoccia E1, Turco F2, Palumbo I2, Lu J3, Steardo A4, Cuomo R2, Sarnelli G2, Steardo L1. | Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-? activation. | Gut. | 2014 Aug;63(8):1300-12. doi: 10.1136/gutjnl-2013-305005. Epub 2013 Sep 30.

[134] Borrelli F1, Romano B, Petrosino S, Pagano E, Capasso R, Coppola D, Battista G, Orlando P, Di Marzo V, Izzo AA. | Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent. | Br J Pharmacol. | 2015 Jan;172(1):142-58. doi: 10.1111/bph.12907. Epub 2014 Dec 1.

[135] Wang J1, Zheng J, Kulkarni A, Wang W, Garg S, Prather PL, Hauer-Jensen M. | Palmitoylethanolamide regulates development of intestinal radiation injury in a mast cell-dependent manner. | Dig Dis Sci. | 2014 Nov;59(11):2693-703. doi: 10.1007/s10620-014-3212-5. Epub 2014 May 22.

[136] Capasso R1, Orlando P, Pagano E, Aveta T, Buono L, Borrelli F, Di Marzo V, Izzo AA. |Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB? receptors and TRPV1 channels. | Br J Pharmacol. | 2014 Sep;171(17):4026-37. doi: 10.1111/bph.12759.

[137] Peterson CG, Sangfelt P, Wagner M, Hansson T, Lettesjö H, Carlson M. | Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis. | Scand J Clin Lab Invest. |2007;67(8):810-20.

[138] Rognum TO, Brandtzaeg P. | IgE-positive cells in human intestinal mucosa are mainly mast cells. |Int Arch Allergy Appl Immunol. | 1989;89(2-3):256-60.

[139] O’Sullivan SE, Kendall DA. | Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. | Immunobiology. | 2010 Aug;215(8):611-6. Epub 2009 Oct 14.

[140] Capasso R1, Orlando P, Pagano E, Aveta T, Buono L, Borrelli F, Di Marzo V, Izzo AA. |Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB? receptors and TRPV1 channels. | Br J Pharmacol. | 2014 Sep;171(17):4026-37. doi: 10.1111/bph.12759.

[141] Esposito G1, Capoccia E1, Turco F2, Palumbo I2, Lu J3, Steardo A4, Cuomo R2, Sarnelli G2, Steardo L1. | Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-? activation. | Gut. | 2014 Aug;63(8):1300-12. doi: 10.1136/gutjnl-2013-305005. Epub 2013 Sep 30.

[142] Lakhan SE, Kirchgessner A. | Neuroinflammation in inflammatory bowel disease. | J Neuroinflammation. | 2010 Jul 8;7:37.

[143] Kraneveld AD, Rijnierse A, Nijkamp FP, Garssen J. | Neuro-immune interactions in inflammatory bowel disease and irritable bowel syndrome: future therapeutic targets. | Eur J Pharmacol. | 2008 May 13;585(2-3):361-74. Epub 2008 Mar 18.

[144] McKernan DP1, Finn DP1. | An apPEAling new therapeutic for ulcerative colitis? | Gut. | 2014 Aug;63(8):1207-8. doi: 10.1136/gutjnl-2013-305929. Epub 2013 Oct 23.

[145] Foley S, Garsed K, Singh G, Duroudier NP, Swan C, Hall IP, Zaitoun A, Bennett A, Marsden C, Holmes G, Walls A, Spiller RC. | Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation. | Gastroenterology. | 2011 May;140(5):1434-43.e1. Epub 2011 Mar 23.

[146] Chang JY, Talley NJ. | An update on irritable bowel syndrome: from diagnosis to emerging therapies.| Curr Opin Gastroenterol. | 2010 Nov 18. [Epub ahead of print]

[147] Solorzano C, Zhu C, Battista N, Astarita G, Lodola A, Rivara S, Mor M, Russo R, Maccarrone M, Antonietti F, Duranti A, Tontini A, Cuzzocrea S, Tarzia G, Piomelli D. | Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. | Proc Natl Acad Sci U S A. | 2009 Dec 8;106(49):20966-71. Epub 2009 Nov 19.

[148] Blirando K, Milliat F, Martelly I, Sabourin JC, Benderitter M, François A. | Mast cells are an essential component of human radiation proctitis and contribute to experimental colorectal damage in mice. | Am J Pathol. | 2011 Feb;178(2):640-51.

[149] Solorzano C, Zhu C, Battista N, Astarita G, Lodola A, Rivara S, Mor M, Russo R, Maccarrone M, Antonietti F, Duranti A, Tontini A, Cuzzocrea S, Tarzia G, Piomelli D. | Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. | Proc Natl Acad Sci U S A. | 2009 Dec 8;106(49):20966-71. Epub 2009 Nov 19.

[150] Taylor TJ, Youssef NN, Shankar R, Kleiner DE, Henderson WA. | The association of mast cells and serotonin in children with chronic abdominal pain of unknown etiology. | BMC Res Notes. | 2010 Oct 21;3:265.

[151] Chang JY, Talley NJ. | An update on irritable bowel syndrome: from diagnosis to emerging therapies.| Curr Opin Gastroenterol. | 2010 Nov 18. [Epub ahead of print]

[152] De Filippis D, Luongo L, Cipriano M, Palazzo E, Cinelli MP, de Novellis V, Maione S, Iuvone T. |Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. | Mol Pain. | 2011 Jan 10;7:3.

[153] Petrosino S, Iuvone T, Di Marzo V. | N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. | Biochimie. | 2010 Jun;92(6):724-7. Epub 2010 Jan 21.

[154] Endocannabinoid Research Group, De Filippis D, D’Amico A, Cipriano M, Petrosino S, Orlando P, Di Marzo V, Iuvone T. | Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. | Pharmacol Res. | 2010 Apr;61(4):321-8. Epub 2009 Nov 17.

[155] Hoareau L, Buyse M, Festy F, Ravanan P, Gonthier MP, Matias I, Petrosino S, Tallet F, d’Hellencourt CL, Cesari M, Di Marzo V, Roche R. | Anti-inflammatory effect of palmitoylethanolamide on human adipocytes. |Obesity (Silver Spring). | 2009 Mar;17(3):431-8. Epub 2009 Jan 8.

[156] De Filippis D, D’Amico A, Cinelli MP, Esposito G, Di Marzo V, Iuvone T. | Adelmidrol, a palmitoylethanolamide analogue, reduces chronic inflammation in a carrageenin-granuloma model in rats. |J Cell Mol Med. | 2009 Jun;13(6):1086-95. Epub 2008 Apr 18.

[157] Machelska H. | Dual peripheral actions of immune cells in neuropathic pain. | Arch Immunol Ther Exp (Warsz). | 2011 Feb;59(1):11-24. Epub 2011 Jan 14.

[158] Ständer S, Raap U, Weisshaar E, Schmelz M, Mettang T, Handwerker H, Luger TA. | Pathogenesis of pruritus. | J Dtsch Dermatol Ges. | 2011 Jun;9(6):456-463. doi: 10.1111/j.1610-0387.2011.07585.x. Epub 2011 Jan 5.

[159] Järvikallio A, Naukkarinen A, Harvima IT, Aalto ML, Horsmanheimo M. | Quantitative analysis of tryptase- and chymase-containing mast cells in atopic dermatitis and nummular eczema. | Br J Dermatol. |1997 Jun;136(6):871-7.

[160] Eberlein B, Eicke C, Reinhardt HW, Ring J. | Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). | J Eur Acad Dermatol Venereol. | 2008 Jan;22(1):73-82.

[161] Petrosino S, Cristino L, Karsak M, Gaffal E, Ueda N, Tüting T, Bisogno T, De Filippis D, D’Amico A, Saturnino C, Orlando P, Zimmer A, Iuvone T, Di Marzo V. | Protective role of palmitoylethanolamide in contact allergic dermatitis. | Allergy. | 2010 Jun 1;65(6):698-711. Epub 2009 Nov 11.

[162] Kircik L. | A nonsteroidal lamellar matrix cream containing palmitoylethanolamide for the treatment of atopic dermatitis. | J Drugs Dermatol. | 2010 Apr;9(4):334-8.

[163] Hatano Y, Man MQ, Uchida Y, Crumrine D, Mauro TM, Feingold KR, Elias PM, Holleran WM. | Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators. | J Allergy Clin Immunol. | 2010 Jan;125(1):160-9.e1-5. Epub 2009 Oct 8.

[164] Dahten A, Koch C, Ernst D, Schnöller C, Hartmann S, Worm M. | Systemic PPARgamma ligation inhibits allergic immune response in the skin. | J Invest Dermatol. | 2008 Sep;128(9):2211-8. Epub 2008 Apr 10.

[165] Cerrato S, Brazis P, Valle MF, Miolo A, Petrosino S, Marzo VD, Puigdemont A. | Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs. | Vet J. | 2011 May 19. [Epub ahead of print]

[166] Yuan C1, Wang XM1, Guichard A2, Tan YM1, Qian CY1, Yang LJ1, Humbert P2. | N-palmitoylethanolamine and N-acetylethanolamine are effective in asteatotic eczema: results of a randomized, double-blind, controlled study in 60 patients. | Clin Interv Aging. | 2014 Jul 17;9:1163-9. doi: 10.2147/CIA.S65448. eCollection 2014.

[167] Harvima IT, Nilsson G, Naukkarinen A. | Role of mast cells and sensory nerves in skin inflammation. |G Ital Dermatol Venereol. | 2010 Apr;145(2):195-204.

[168] Kneilling M, Röcken M. | Mast cells: novel clinical perspectives from recent insights. | Exp Dermatol.| 2009 May;18(5):488-96.

[169] Harvima IT, Nilsson G, Suttle MM, Naukkarinen A. | Is there a role for mast cells in psoriasis? | Arch Dermatol Res. | 2008 Oct;300(9):461-78. Epub 2008 Aug 22.

[170] Broide DH, Finkelman F, Bochner BS, Rothenberg ME. | Advances in mechanisms of asthma, allergy, and immunology in 2010. | J Allergy Clin Immunol. | 2011 Mar;127(3):689-95.

[171] Di Capite JL, Bates GJ, Parekh AB. | Mast cell CRAC channel as a novel therapeutic target in allergy. |Curr Opin Allergy Clin Immunol. | 2011 Feb;11(1):33-8.

[172] Zhao J, Endoh I, Hsu K, Tedla N, Endoh Y, Geczy CL. | S100A8 modulates mast cell function and suppresses eosinophil migration in acute asthma. | Antioxid Redox Signal. | 2011 May 1;14(9):1589-600. Epub 2011 Feb 28.

[173] Yoshihara S, Morimoto H, Ohori M, Yamada Y, Abe T, Arisaka O. | Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways. | Int Arch Allergy Immunol. | 2005 Sep;138(1):80-7. Epub 2005 Aug 11.

[174] Impellizzeri D, Esposito E, Di Paola R, Ahmad A, Campolo M, Peli A, Morittu VM, Britti D, Cuzzocrea S.| Palmitoylethanolamide and luteolin ameliorate development of arthritis caused by injection of collagen type II in mice. | Arthritis Res Ther. | 2013;15(6):R192.

[175] Metz M, Gilles S, Geldmacher A, Behrendt H, Traidl-Hoffmann C, Maurer M. | Evidence for non-allergic mast cell activation in pollen-associated inflammation. | J Invest Dermatol. | 2011 Apr;131(4):987-90. Epub 2011 Jan 20.

[176] Ozben B, Erdogan O. | The role of inflammation and allergy in acute coronary syndromes. | Inflamm Allergy Drug Targets. | 2008 Sep;7(3):136-44.

[177] Kounis NG. | Kounis syndrome (allergic angina and allergic myocardial infarction): a natural paradigm? | Int J Cardiol. | 2006 Jun 7;110(1):7-14. Epub 2005 Oct 24.

[178] Biteker M. | Current understanding of Kounis syndrome. | Expert Rev Clin Immunol. | 2010 Sep;6(5):777-88.

[179] Lépicier P, Bouchard JF, Lagneux C, Lamontagne D. | Endocannabinoids protect the rat isolated heart against ischaemia. | Br J Pharmacol. | 2003 Jun;139(4):805-15.

[180] Bouchard JF, Lépicier P, Lamontagne D. | Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. | Life Sci. | 2003 Mar 7;72(16):1859-70.

[181] Wilensky RL, Hamamdzic D. | The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation. | Curr Opin Cardiol. | 2007 Nov;22(6):545-51.

[182] Mattace Raso G, Simeoli R, Russo R, Santoro A, Pirozzi C, d’Emmanuele di Villa Bianca R, Mitidieri E, Paciello O, Pagano TB, Orefice NS, Meli R, Calignano A. | N-Palmitoylethanolamide protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress. | Pharmacol Res. |2013 Oct;76:67-76. doi: 10.1016/j.phrs.2013.07.007. Epub 2013 Aug 2.

[183] Pescosolido N, Librando A, Puzzono M, Nebbioso M. | Palmitoylethanolamide Effects on Intraocular Pressure After Nd:YAG Laser Iridotomy: An Experimental Clinical Study. | J Ocul Pharmacol Ther. | 2011 Aug 10. [Epub ahead of print]

[184] Chen J, Matias I, Dinh T, Lu T, Venezia S, Nieves A, Woodward DF, Di Marzo V. | Finding of endocannabinoids in human eye tissues: implications for glaucoma. | Biochem Biophys Res Commun. | 2005 May 20;330(4):1062-7.

[185] Caterina Gagliano et al | Ocular hypotensive effect of oral palmitoylethanolamide: a clinical trial. |Invest. Ophthalmol. Vis. Sci. June 24, 2011 iovs.10-7057

[186]

[187] Costagliola C1, Romano MR, dell’Omo R, Russo A, Mastropasqua R, Semeraro F. | Effect of palmitoylethanolamide on visual field damage progression in normal tension glaucoma patients: results of an open-label six-month follow-up. | J Med Food. | 2014 Sep;17(9):949-54. doi: 10.1089/jmf.2013.0165. Epub 2014 May 14.

[188] Impellizzeri D1, Ahmad A1, Bruschetta G1, Di Paola R1, Crupi R1, Paterniti I1, Esposito E1, Cuzzocrea S2. | The anti-inflammatory effects of palmitoylethanolamide (PEA) on endotoxin-induced uveitis in rats. | Eur J Pharmacol. | 2015 Apr 28;761:28-35. doi: 10.1016/j.ejphar.2015.04.025. [Epub ahead of print]

[189] Yu HL, Deng XQ, Li YJ, Li YC, Quan ZS, Sun XY. | N-palmitoylethanolamide, an endocannabinoid, exhibits antidepressant effects in the forced swim test and the tail suspension test in mice. | Pharmacol Rep.| 2011 May-Jun;63(3):834-9.

[190] Crupi R, Paterniti I, Ahmad A, Campolo M, Esposito E, Cuzzocrea S. | Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression. | CNS Neurol Disord Drug Targets. | 2013 Jul 10. [Epub ahead of print]

[191] Smaga I1, Bystrowska B, Gawli?ski D, Pomierny B, Stankowicz P, Filip M. | Antidepressants and changes in concentration of endocannabinoids and N-acylethanolamines in rat brain structures. | Neurotox Res. | 2014 Aug;26(2):190-206. doi: 10.1007/s12640-014-9465-0. Epub 2014 Mar 21.

[192] Coppola M1, Mondola R2. | Is there a role for palmitoylethanolamide in the treatment of depression?| Med Hypotheses. | 2014 May;82(5):507-11. doi: 10.1016/j.mehy.2013.12.016. Epub 2014 Mar 3.

[193] Citraro R, Russo E, Scicchitano F, van Rijn CM, Cosco D, Avagliano C, Russo R, D’Agostino G, Petrosino S, Guida F, Gatta L, van Luijtelaar G, Maione S, Di Marzo V, Calignano A, De Sarro G. |Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-? receptor activation in a genetic model of absence epilepsy. | Neuropharmacology. | 2013 Jun;69:115-26. doi: 10.1016/j.neuropharm.2012.11.017. Epub 2012 Dec 1.

[194] Lambert DM, Vandevoorde S, Diependaele G, Govaerts SJ, Robert AR. | Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. | Epilepsia. | 2001 Mar;42(3):321-7.

[195] Sheerin AH, Zhang X, Saucier DM, Corcoran ME. | Selective antiepileptic effects of N-palmitoylethanolamide, a putative endocannabinoid. | Epilepsia. | 2004 Oct;45(10):1184-8.

[196] Murillo-Rodríguez E, Palomero-Rivero M, Millán-Aldaco D, Arias-Carrión O, Drucker-Colín R. |Administration of URB597, Oleoylethanolamide or Palmitoylethanolamide Increases Waking and Dopamine in Rats. | PLoS One. | 2011;6(7):e20766. Epub 2011 Jul 14.

[197] Ahmad A, Genovese T, Impellizzeri D, Crupi R, Velardi E, Marino A, Esposito E, Cuzzocrea S. |Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats. | Brain Res. | 2012 Oct 5;1477:45-58. doi: 10.1016/j.brainres.2012.08.006. Epub 2012 Aug 13.

[198] Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N. | Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. | J Neurosci. | 2003 Aug 27;23(21):7767-75.

[199] Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di Marzo V. | Endocannabinoids control spasticity in a multiple sclerosis model. | FASEB J. | 2001 Feb;15(2):300-2. Epub 2000 Dec 8.

[200] Clemente S. | Amyotrophic lateral sclerosis treatment with micronized palmitoylethanolamide: A case report. | CNS Neurol Disord Drug Targets. | 2012 Sep 17. [Epub ahead of print]

[201] Rahimi A1, Faizi M1, Talebi F2, Noorbakhsh F3, Kahrizi F1, Naderi N1. | Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice. | Neuroscience. | 2015 Apr 2;290:279-87. doi: 10.1016/j.neuroscience.2015.01.030. Epub 2015 Jan 28.

[202] Romani R, Galeazzi R, Rosi G, Fiorini R, Pirisinu I, Ambrosini A, Zolese G. | Anandamide and its congeners inhibit human plasma butyrylcholinesterase. Possible new roles for these endocannabinoids? |Biochimie. | 2011 Sep;93(9):1584-91. Epub 2011 May 31.

[203] Scuderi C, Esposito G, Blasio A, Valenza M, Arietti P, Steardo L Jr, Carnuccio R, De Filippis D, Petrosino S, Iuvone T, Di Marzo V, Steardo L. | Palmitoylethanolamide counteracts reactive astrogliosis induced by beta-amyloid peptide. | J Cell Mol Med. | 2011 Jan 21. doi: 10.1111/j.1582-4934.2011.01267.x. [Epub ahead of print]

[204] Skaper SD, Facci L, Giusti P. | Mast cells, glia and neuroinflammation: partners in crime? |Immunology. | 2013 Sep 11. doi: 10.1111/imm.12170. [Epub ahead of print]

[205] Scuderi C, Steardo L. | Neuroglial Roots of Neurodegenerative Diseases: Therapeutic Potential of Palmitoylethanolamide in Models Of Alzheimer’s Disease. | CNS Neurol Disord Drug Targets. | 2013 Feb 4. [Epub ahead of print]

[206] Cipriano M, Esposito G, Negro L, Capoccia E, Sarnelli G, Scuderi C, de Filippis D, Steardo L, Iuvone T1. | Palmitoylethanolamide regulates production of pro-angiogenic mediators in a model of ? amyloid-induced astrogliosis in vitro. | CNS Neurol Disord Drug Targets. | 2015 Mar 17. [Epub ahead of print]

[207] Tomasini MC1, Borelli AC2, Beggiato S1, Ferraro L3, Cassano T4, Tanganelli S5, Antonelli T5. |Differential Effects of Palmitoylethanolamide against Amyloid-? Induced Toxicity in Cortical Neuronal and Astrocytic Primary Cultures from Wild-Type and 3xTg-AD Mice. | J Alzheimers Dis. | 2015 Mar 12. [Epub ahead of print]

[208] Scuderi C1, Stecca C1, Valenza M2, Ratano P1, Bronzuoli MR1, Bartoli S1, Steardo L3, Pompili E4, Fumagalli L4, Campolongo P1, Steardo L1. | Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer’s disease. | Cell Death Dis. | 2014 Sep 11;5:e1419. doi: 10.1038/cddis.2014.376.

[209] Paterniti I, Cordaro M, Campolo M, Siracusa R, Cornelius C, Navarra M, Cuzzocrea S, Esposito E1. |Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer’s disease models: the control of neuroinflammation. | CNS Neurol Disord Drug Targets. | 2014;13(9):1530-41.

[210] Skaper SD, Facci L, Giusti P. | Glia and Mast Cells as Targets for Palmitoylethanolamide, an Anti-inflammatory and Neuroprotective Lipid Mediator. | Mol Neurobiol. | 2013 Oct;48(2):340-52. doi: 10.1007/s12035-013-8487-6. Epub 2013 Jun 28.

[211] Skaper SD, Facci L. | Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide. | Philos Trans R Soc Lond B Biol Sci. | 2012 Dec 5;367(1607):3312-25. doi: 10.1098/rstb.2011.0391.

[212] Rahimi A1, Faizi M1, Talebi F2, Noorbakhsh F3, Kahrizi F1, Naderi N1. | Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice. | Neuroscience. | 2015 Apr 2;290:279-87. doi: 10.1016/j.neuroscience.2015.01.030. Epub 2015 Jan 28.

[213] Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Galuppo M, Cuzzocrea S. | Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. |Brain Behav Immun. | 2011 Feb 25. [Epub ahead of print]

[215] Redlich S1, Ribes S, Schütze S, Nau R. | Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 by macrophages and increases the resistance of mice against infections. | J Neuroinflammation. | 2014 Jun 14;11:108. doi: 10.1186/1742-2094-11-108.

[216] Hamtiaux L, Masquelier J, Muccioli GG, Bouzin C, Feron O, Gallez B, Lambert DM. | The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action. | BMC Cancer. | 2012 Mar 19;12:92.

[217] Hamtiaux L, Hansoulle L, Dauguet N, Muccioli GG, Gallez B, Lambert DM. | Increasing antiproliferative properties of endocannabinoids in N1E-115 neuroblastoma cells through inhibition of their metabolism. | PLoS One. | 2011;6(10):e26823. Epub 2011 Oct 27.

[218] De Petrocellis L, Bisogno T, Ligresti A, Bifulco M, Melck D, Di Marzo V. | Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. | Fundam Clin Pharmacol. | 2002 Aug;16(4):297-302.

[219] Parolaro D, Massi P, Rubino T, Monti E. | Endocannabinoids in the immune system and cancer. |Prostaglandins Leukot Essent Fatty Acids. | 2002 Feb-Mar;66(2-3):319-32.

[220] Jacobsson SO, Wallin T, Fowler CJ. | Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. | J Pharmacol Exp Ther.| 2001 Dec;299(3):951-9.

[221] Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M, Vogel Z, De Petrocellis L. |Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. | Biochem J. | 2001 Aug 15;358(Pt 1):249-55.

[222] De Petrocellis L, Melck D, Bisogno T, Di Marzo V. | Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. | Chem Phys Lipids. | 2000 Nov;108(1-2):191-209.

[223] Di Marzo V, Melck D, De Petrocellis L, Bisogno T. | Cannabimimetic fatty acid derivatives in cancer and inflammation. | Prostaglandins Other Lipid Mediat. | 2000 Apr;61(1-2):43-61.

[224] Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V. | Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. | Endocrinology. | 2000 Jan;141(1):118-26.

[225] Benvenuti F, Lattanzi F, De Gori A, Tarli P. | [Activity of some derivatives of palmitoylethanolamide on carragenine-induced edema in the rat paw]. | Boll Soc Ital Biol Sper. | 1968 May 15;44(9):809-13.

[226] Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. | Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. | Proc Natl Acad Sci U S A. | 1995 Apr 11;92(8):3376-80.

[227] Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A. | N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation.| Eur J Pharmacol. | 1996 Apr 11;300(3):227-36.

[228] Ross RA, Brockie HC, Pertwee RG. | Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. | Eur J Pharmacol. | 2000 Aug 4;401(2):121-30.

[229] Scarampella F, Abramo F, Noli C. | Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study. | Vet Dermatol. | 2001 Feb;12(1):29-39.

[230] Lambert DM, Vandevoorde S, Jonsson KO, Fowler CJ. | The palmitoylethanolamide family: a new class of anti-inflammatory agents? | Curr Med Chem. | 2002 Mar;9(6):663-74.

[231] Re G, Barbero R, Miolo A, Di Marzo V. | Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. | Vet J. | 2007 Jan;173(1):21-30. Epub 2005 Dec 1.

[232] De Filippis D1, Russo A1, De Stefano D2, Cipriano M1, Esposito D3, Grassia G1, Carnuccio R1, Russo G1, Iuvone T4. | Palmitoylethanolamide inhibits rMCP-5 expression by regulating MITF activation in rat chronic granulomatous inflammation. | Eur J Pharmacol. | 2014 Feb 15;725:64-9. doi: 10.1016/j.ejphar.2013.12.021. Epub 2014 Jan 16.

[233] Rasková H, Masek K, Linèt O. | Non-specific resistance induced by palmitoylethanolamide. |Toxicon. | 1972 Aug;10(5):485-90.

[234] Mattace Raso G1, Pirozzi C1, d’Emmanuele di Villa Bianca R1, Simeoli R2, Santoro A1, Lama A1, Di Guida F1, Russo R1, De Caro C1, Sorrentino R1, Calignano A1, Meli R1. | Palmitoylethanolamide treatment reduces blood pressure in spontaneously hypertensive rats: involvement of cytochrome p450-derived eicosanoids and Renin Angiotensin system. | PLoS One. | 2015 May 7;10(5):e0123602. doi: 10.1371/journal.pone.0123602. eCollection 2015.

[235] Di Cesare Mannelli L1, Corti F1, Micheli L1, Zanardelli M1, Ghelardini C1. | Delay of morphine tolerance by palmitoylethanolamide. | Biomed Res Int. | 2015;2015:894732. doi: 10.1155/2015/894732. Epub 2015 Mar 22.